Search

Search Constraints

You searched for: Author/Creator Graham, N.M.H.

Search Results

1. Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate‐to‐severe atopic dermatitis. (1st May 2019)

2. Laboratory safety of dupilumab in moderate‐to‐severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS). (1st December 2019)

4. A study of dupilumab in the treatment of adolescents with eczema. (2nd January 2020)

5. 一项关于 dupilumab 治疗湿疹青少年患者的研究. (2nd January 2020)

6. Dupilumab in adolescents with uncontrolled moderate‐to‐severe atopic dermatitis: results from a phase IIa open‐label trial and subsequent phase III open‐label extension. (8th October 2019)

7. Dupilumab provides favourable long‐term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled severe atopic dermatitis: results from an open‐label phase IIa study and subsequent phase III open‐label extension study. (9th October 2020)

8. Validation of the Peak Pruritus Numerical Rating Scale. (1st October 2019)

10. Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate‐to‐severe atopic dermatitis. (1st October 2019)